Observational studyInternational journal of clinical oncology2025

Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.

Yoshikazu Nagase et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.